Therapeutic Inertia in Dyslipidemia Management for Secondary Cardiovascular Prevention: Results from the Italian ITACARE-P Network

被引:2
作者
Faggiano, Andrea [1 ,2 ]
Gualeni, Anna [3 ]
Barbieri, Lucia [1 ,2 ]
Mureddu, Gian Francesco [4 ]
Venturini, Elio [5 ]
Giallauria, Francesco [6 ]
Ambrosetti, Marco [7 ]
Ruzzolini, Matteo [8 ]
Maranta, Francesco [9 ]
Silverii, Maria Vittoria [10 ]
Garau, Laura [1 ,2 ]
Garamella, Davide [5 ]
Napoli, Raffaele [6 ]
Maresca, Luigi [7 ]
Panetta, Gaetano Luca [8 ]
Maggi, Antonio [3 ]
Carugo, Stefano [1 ,2 ]
Fattirolli, Francesco [10 ,11 ]
Faggiano, Pompilio [3 ]
机构
[1] Fdn IRCCS CaGranda Osped Maggiore Policlin, SC Ematol, Milan, Italy
[2] Univ Milan, Dept Clin Sci & Community Hlth, I-20122 Milan, Italy
[3] Fdn Poliambulanza, Cardiovasc Dept, I-25124 Brescia, Italy
[4] San Giovanni Hosp Complex, Cardiol & Cardiac Rehabil Unit, I-00184 Rome, Italy
[5] Cecina Civil Hosp, Cardiac Rehabil Unit, I-57023 Cecina, LI, Italy
[6] Federico II Univ Naples, Dept Translat Med Sci, Precis Med Unit, Via S Pansini 5, I-80131 Naples, Italy
[7] Santa Marta Hosp, Cardiovasc Rehabil Unit, ASST Crema, Rivolta Dadda, Italy
[8] Isola Tiberina Gemelli Isola Hosp, Cardiol Dept, I-00186 Rome, Italy
[9] Ist Sci San Raffaele, Cardiovasc Rehabil Unit, I-20132 Milan, Italy
[10] Careggi Univ Hosp, SOD Cardiol Rehabil Unit, I-50134 Florence, Italy
[11] Univ Florence, Dept Expt & Clin Med, I-50134 Florence, Italy
关键词
therapeutic inertia; dyslipidemia; low-density lipoprotein cholesterol; secondary cardiovascular prevention; lipid-lowering therapies; LIPID-LOWERING THERAPY; PERIPHERAL ARTERIAL; EUROPEAN-SOCIETY; ESC GUIDELINES; RISK; CHOLESTEROL; DISEASES;
D O I
10.3390/jcm14020493
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background/Objectives: This study assessed the proportion of secondary cardiovascular prevention patients who achieved low-density lipoprotein (LDL) cholesterol targets as per the 2019 ESC/EAS Dyslipidemia Guidelines. We also evaluated whether lipid-lowering therapies (LLTs) were adjusted in patients not meeting targets and analyzed the likelihood of these modifications achieving recommended levels. Methods: A multicenter, cross-sectional observational study retrospectively reviewed medical records of 1909 outpatients in 9 Italian cardiac rehabilitation/secondary prevention clinics from January 2023 to June 2024. Inclusion criteria included prior atherosclerotic cardiovascular disease (ASCVD) and recent LDL-cholesterol levels. Data included demographics, ASCVD presentation, lipid profiles, and LLTs. Patients at very high risk had LDL targets of <= 55 mg/dL, or <= 40 mg/dL for recurrent events within 2 years. Clinicians' approaches to LLT modification in patients not at target were recorded, with LLT efficacy estimated based on percentage distance from LDL-cholesterol targets. Results: Of the 1909 patients, 41.3% met the LDL-cholesterol target. Predictors of achieving targets included male gender, cardiac rehabilitation, recent acute coronary syndrome, diabetes, and triple therapy (statin + ezetimibe + PCSK9 inhibitors). Conversely, a target of <= 40 mg/dL, lack of therapy, and monotherapy were negative predictors. Among 1074 patients not at target, LLT modifications were proposed for 48.6%. Predictors of LLT modification included recent ASCVD events, cardiac rehabilitation, and greater percentage distance from the LDL target, while advanced age and an LDL target of <= 40 mg/dL were negative predictors. However, only 42.3% of modified therapies were predicted to be effective in reaching LDL targets. Conclusions: Despite 2019 ESC/EAS guidelines, a significant proportion of high-risk patients did not achieve LDL targets, and proposed LLT modifications were often insufficient. More intensive LLT regimens are needed to improve outcomes in this population.
引用
收藏
页数:16
相关论文
共 46 条
[1]   Questions and answers on diagnosis and management of patients with Peripheral Arterial Diseases: a companion document of the 2017 ESC Guidelines for the Diagnosis and Treatment of Peripheral Arterial Diseases, in collaboration with the European Society for Vascular Surgery (ESVS) [J].
Aboyans, Victor ;
Bjorck, Martin ;
Brodmann, Marianne ;
Collet, Jean-Philippe ;
Czerny, Martin ;
De Carlo, Marco ;
Naylor, A. Ross ;
Roffi, Marco ;
Tendera, Michal ;
Vlachopoulos, Charalambos ;
Ricco, Jean-Baptiste ;
El Bartelink, Marie-Louise ;
Cohnert, Tina ;
Debus, Sebastian ;
Espinola-Klein, Christine ;
Kahan, Thomas ;
Kownator, Serge ;
Mazzolai, Lucia ;
Roether, Joachim ;
Sprynger, Muriel ;
Tepe, Gunnar ;
Venermo, Maarit ;
Desormais, Ileana .
EUROPEAN HEART JOURNAL, 2018, 39 (09) :E35-E41
[2]   Evaluating statin effect on LDL-cholesterol: when predicted is not measured [J].
Abrignani, Maurizio Giuseppe .
EUROPEAN JOURNAL OF PREVENTIVE CARDIOLOGY, 2020, 27 (15) :1627-1629
[3]   Barriers in utilizing lipid-lowering agents in non-institutionalized population in the US: Application of a theoretical framework [J].
Alfaifi, Abdullah A. ;
Lai, Leanne ;
Althemery, Abdullah U. .
PLOS ONE, 2021, 16 (08)
[4]   Application of the 2019 ESC/EAS dyslipidaemia guidelines to nationwide data of patients with a recent myocardial infarction: a simulation study [J].
Allahyari, Ali ;
Jernberg, Tomas ;
Hagstrom, Emil ;
Leosdottir, Margret ;
Lundman, Pia ;
Ueda, Peter .
EUROPEAN HEART JOURNAL, 2020, 41 (40) :3900-3909
[5]  
Arca M, 2023, European Atherosclerosis Journal, V1, P1, DOI DOI 10.56095/EAJ.V2I1.26
[6]   PCSK9 inhibitor access barriersissues and recommendations: Improving the access process for patients, clinicians and payers [J].
Baum, Seth J. ;
Toth, Peter P. ;
Underberg, James A. ;
Jellinger, Paul ;
Ross, Joyce ;
Wilemon, Katherine .
CLINICAL CARDIOLOGY, 2017, 40 (04) :243-254
[7]   Severe heterozygous familial hypercholesterolemia and risk for cardiovascular disease: A study of a cohort of 14,000 mutation carriers [J].
Besseling, Joost ;
Kindt, Iris ;
Hof, Michel ;
Kastelein, John J. P. ;
Hutten, Barbara A. ;
Hovingh, G. Kees .
ATHEROSCLEROSIS, 2014, 233 (01) :219-223
[8]   Proportion of High-Risk/Very High-Risk Patients in Europe with Low-Density Lipoprotein Cholesterol at Target According to European Guidelines: A Systematic Review [J].
Bruckert, Eric ;
Parhofer, Klaus Georg ;
Gonzalez-Juanatey, Jose Ramon ;
Nordestgaard, Borge ;
Arca, Marcello ;
Giovas, Periklis ;
Ray, Kausik .
ADVANCES IN THERAPY, 2020, 37 (05) :1724-1736
[9]   How Can We Increase the Utilization of Evidence-Based Medication After Myocardial Infarction? [J].
Cavender, Matthew A. ;
Smith, Sidney C. .
JAMA NETWORK OPEN, 2024, 7 (11)
[10]   Percentage low-density lipoprotein-cholesterol response to a given statin dose is not fixed across the pre-treatment range: Real world evidence from clinical practice: Data from the ESC-EORP EUROASPIRE V Study [J].
De Bacquer, Dirk ;
De Smedt, Delphine ;
Reiner, Zeljko ;
Tokgozoglu, Lale ;
Clays, Els ;
Kotseva, Kornelia ;
Ryden, Lars ;
Wood, David ;
De Backer, Guy .
EUROPEAN JOURNAL OF PREVENTIVE CARDIOLOGY, 2020, 27 (15) :1630-1636